# Lin Shen

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lin-shen/

## Facts

| Field | Value |
| --- | --- |
| Citations | 27,749 |
| Field | Gastric Cancer Management and Outcomes |
| h-index | 63 |
| i10-index | 287 |
| Last Known Institution | Shanghai University of Traditional Chinese Medicine |
| OpenAlex ID | https://openalex.org/A5073838859 |
| ORCID iD | https://orcid.org/0000-0002-8798-4756 |
| Works | 804 |

## Researcher papers

- [Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer](https://scholariq.org/papers/randomized-phase-iii-keynote-181-study-of-pembrolizumab-versus-chemotherapy-in/)
- [Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial](https://scholariq.org/papers/perioperative-or-postoperative-adjuvant-oxaliplatin-with-s-1-versus-adjuvant/)
- [Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)](https://scholariq.org/papers/efficacy-safety-and-correlative-biomarkers-of-toripalimab-in-previously-treated/)
- [Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study](https://scholariq.org/papers/tislelizumab-versus-chemotherapy-as-second-line-treatment-for-advanced-or/)
- [Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study](https://scholariq.org/papers/surufatinib-in-advanced-pancreatic-neuroendocrine-tumours-sanet-p-a-randomised/)

## Researcher topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Researcher university

- [Shanghai University of Traditional Chinese Medicine](https://scholariq.org/institutions/shanghai-university-of-traditional-chinese-medicine/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.